Laura Tadvalkar, PhD
Non-Executive Director
Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Laura works on new company creation and early-stage investments, and serves as a Board Director for Typewriter Therapeutics, Hyku Biosciences, GIVAX, and Imbria Pharmaceuticals. She previously served as a Board Director for Mariana Oncology prior to its acquisition by Novartis, and as Board Chair for Aliada Therapeutics prior to its acquisition by AbbVie. Prior to RA Capital, Laura was a Principal at MP Healthcare Venture Management and a Consultant at Clarion Healthcare. Laura holds a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University.
